This is a Phase 3 randomized, parallel-group, double-blind, placebo-controlled trial (Blinded
Treatment Period) followed by an Open-Label Extension Period intended to evaluate the
efficacy and safety of oral PRN1008 in moderate to severe pemphigus. After completing the
Open-Label Extension Period, eligible patients may continue in a Long Term Extension Period
of 48 weeks.
Phase:
Phase 3
Details
Lead Sponsor:
Principia Biopharma, a Sanofi Company Principia Biopharma, Inc.